MedTrace Logo

A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

NCT01258777 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2013-09-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics of golimumab in Japanese and Caucasian Males.

Conditions

  • Healthy Volunteers

Interventions

DRUG

400 mg golimumab or placebo

Single dose of 400 mg subcutaneously

DRUG

200 mg golimumab or placebo

Single dose of 200 mg subcutaneously

Sponsors & Collaborators

  • Centocor, Inc.

    lead INDUSTRY

Principal Investigators

  • Centocor, Inc. Clinical Trial · Centocor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01258777 on ClinicalTrials.gov